Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-19
DOI
10.1038/s41375-018-0216-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
- (2017) A Besse et al. LEUKEMIA
- CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
- (2017) Chang-Xin Shi et al. MOLECULAR CANCER THERAPEUTICS
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- (2016) N. Weinhold et al. BLOOD
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- (2016) K. M. Kortum et al. BLOOD
- Trends in overall survival and costs of multiple myeloma, 2000–2014
- (2016) R Fonseca et al. LEUKEMIA
- Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome
- (2016) S Barrio et al. LEUKEMIA
- Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism
- (2016) G P Soriano et al. LEUKEMIA
- Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers
- (2016) Peter Tsvetkov et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The inhibition mechanism of human 20Sproteasomes enables next-generation inhibitor design
- (2016) Jil Schrader et al. SCIENCE
- Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
- (2016) K M Kortuem et al. Blood Cancer Journal
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- A Big Bang model of human colorectal tumor growth
- (2015) Andrea Sottoriva et al. NATURE GENETICS
- Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914
- (2015) Eva M. Huber et al. STRUCTURE
- Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib
- (2015) Wayne Harshbarger et al. STRUCTURE
- Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97
- (2015) K Parzych et al. Cell Death & Disease
- Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
- (2015) Peter Tsvetkov et al. eLife
- Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple Myeloma Cell Lines
- (2015) Stefan Hausmann et al. PLoS One
- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
- (2014) L Melchor et al. LEUKEMIA
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
- (2014) Niccolo Bolli et al. Nature Communications
- p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition
- (2014) Senthil K Radhakrishnan et al. eLife
- Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules
- (2013) E Leich et al. Blood Cancer Journal
- Sequence analysis of -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
- (2012) D. I. Lichter et al. BLOOD
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- (2012) J. B. Egan et al. BLOOD
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
- (2012) D. J. Kuhn et al. BLOOD
- RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5
- (2011) Y. X. Zhu et al. BLOOD
- Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen
- (2011) Lü Shuqing et al. EXPERIMENTAL HEMATOLOGY
- Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy
- (2011) Patricia Balsas et al. LEUKEMIA RESEARCH
- Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells
- (2011) Erika Suzuki et al. PLoS One
- Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian Cells
- (2010) Senthil K. Radhakrishnan et al. MOLECULAR CELL
- Expression, purification and use of recombinant annexin V for the detection of apoptotic cells
- (2009) Susan E Logue et al. Nature Protocols
- Molecular basis of bortezomib resistance: proteasome subunit 5 (PSMB5) gene mutation and overexpression of PSMB5 protein
- (2008) R. Oerlemans et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now